meRfi®-GM
Graft-Versus-Host Disease (GVHD)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Allogeneic T cell expansion is the primary determinant of graft-versus-host disease (GVHD). The current understanding is that this expansion is driven by histocompatibility antigen disparities between donor and recipient. This paradigm represents a closed genetic system where donor T cells interact with peptide-major histocompatibility complexes (MHCs).
Graft versus host disease (GVHD) is a post-transplant condition where donor T cells attack recipient tissues, traditionally viewed as an immunological issue requiring immunosuppressive treatment
Graft-Versus-Host Disease (GVHD) is traditionally divided into an acute and a chronic disease (see also: [Graft-Vers…
References (Sources)
- An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
- Associations between the Gut Microbiota, Immune Reconstitution, and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation
- Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease
- Optimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation
- Regenerating islet derived 3-alpha is a biomarker of gastrointestinal graft-versus host disease
- ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease
- The primacy of the gastrointestinal tract as a target organ of acute graft-versus host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation